Literature DB >> 30245561

Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers.

James W Cornish1, David Henson1, Sanford Levine1,2, Joseph Volpicelli1, Charles E Inturrisi3, Byron C Yoburn4, Charles P O'Brien1.   

Abstract

Entities:  

Year:  1993        PMID： 30245561      PMCID： PMC6147145     

Source DB:  PubMed          Journal:  Am J Addict        ISSN： 1055-0496


× No keyword cloud information.
  16 in total

1.  Enhanced analgesic effects of morphine after chronic administration of naloxone in the rat.

Authors:  A H Tang; R J Collins
Journal:  Eur J Pharmacol       Date:  1978-02-15       Impact factor: 4.432

2.  Chronic opioid antagonist treatment increases mu and delta receptor mediated spinal opioid analgesia.

Authors:  B C Yoburn; D Paul; S Azimuddin; K Lutfy; V Sierra
Journal:  Brain Res       Date:  1989-04-17       Impact factor: 3.252

3.  Disposition of (15,16-3H)naltrexone in the central nervous system of the rat.

Authors:  A L Misra; R Bloch; J Vardy; S J Mulé; K Verebely
Journal:  Drug Metab Dispos       Date:  1976 May-Jun       Impact factor: 3.922

4.  Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment.

Authors:  A Tempel; R S Zukin; E L Gardner
Journal:  Life Sci       Date:  1982 Sep 20-27       Impact factor: 5.037

5.  Pharmacodynamic supersensitivity and opioid receptor upregulation in the mouse.

Authors:  B C Yoburn; F A Nunes; B Adler; G W Pasternak; C E Inturrisi
Journal:  J Pharmacol Exp Ther       Date:  1986-10       Impact factor: 4.030

6.  Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation.

Authors:  A Tempel; E L Gardner; R S Zukin
Journal:  J Pharmacol Exp Ther       Date:  1985-02       Impact factor: 4.030

7.  Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment.

Authors:  B C Yoburn; R R Goodman; A H Cohen; G W Pasternak; C E Inturrisi
Journal:  Life Sci       Date:  1985-06-17       Impact factor: 5.037

8.  The urinary excretion profiles of naltrexone in man, monkey, rabbit, and rat.

Authors:  H E Dayton; C E Inturrisi
Journal:  Drug Metab Dispos       Date:  1976 Sep-Oct       Impact factor: 3.922

9.  Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.

Authors:  M C Meyer; A B Straughn; M W Lo; W L Schary; C C Whitney
Journal:  J Clin Psychiatry       Date:  1984-09       Impact factor: 4.384

10.  Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat.

Authors:  B C Yoburn; A H Cohen; C E Inturrisi
Journal:  J Pharmacol Exp Ther       Date:  1986-04       Impact factor: 4.030
View more
  2 in total

1.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Authors:  Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien
Journal:  Arch Gen Psychiatry       Date:  2006-02

2.  Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018.

Authors:  Priya Jain; Kimberley McKinnell; Rose Marino; Prashanthi Vunnava; Marie A Liles-Burden; Avani Desai; Madé Wenten; James Fratantonio; Sarah C Akerman; Maria A Sullivan; Gary Bloomgren
Journal:  Drug Saf       Date:  2020-11-30       Impact factor: 5.606
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.